ATE222603T1 - Hepatozytwachstumfaktor variante - Google Patents

Hepatozytwachstumfaktor variante

Info

Publication number
ATE222603T1
ATE222603T1 AT93911339T AT93911339T ATE222603T1 AT E222603 T1 ATE222603 T1 AT E222603T1 AT 93911339 T AT93911339 T AT 93911339T AT 93911339 T AT93911339 T AT 93911339T AT E222603 T1 ATE222603 T1 AT E222603T1
Authority
AT
Austria
Prior art keywords
growth factor
hepatocyt
hgf
factor variant
variant
Prior art date
Application number
AT93911339T
Other languages
English (en)
Inventor
Paul J Godowski
Nathalie A Lokker
Melanie R Mark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/884,811 external-priority patent/US5316921A/en
Priority claimed from US07/885,971 external-priority patent/US5328837A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE222603T1 publication Critical patent/ATE222603T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT93911339T 1992-05-18 1993-05-17 Hepatozytwachstumfaktor variante ATE222603T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/884,811 US5316921A (en) 1992-05-18 1992-05-18 Single-chain hepatocyte growth factor variants
US07/885,971 US5328837A (en) 1992-05-18 1992-05-18 Hepatocyte growth factor protease domain variants
PCT/US1993/004648 WO1993023541A1 (en) 1992-05-18 1993-05-17 Hepatocyte growth factor variants

Publications (1)

Publication Number Publication Date
ATE222603T1 true ATE222603T1 (de) 2002-09-15

Family

ID=27128741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911339T ATE222603T1 (de) 1992-05-18 1993-05-17 Hepatozytwachstumfaktor variante

Country Status (10)

Country Link
US (1) US5547856A (de)
EP (1) EP0642580B1 (de)
JP (2) JPH07508420A (de)
AT (1) ATE222603T1 (de)
CA (1) CA2118012A1 (de)
DE (1) DE69332221T2 (de)
DK (1) DK0642580T3 (de)
ES (1) ES2181689T3 (de)
PT (1) PT642580E (de)
WO (1) WO1993023541A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
CA2144856A1 (en) * 1992-09-18 1994-03-31 Donna L. Faletto A method of preventing tumor metastasis
ES2206523T3 (es) 1994-12-27 2004-05-16 Daiichi Pharmaceutical Co., Ltd. Mutantes de tecf.
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
EP0941111A4 (de) * 1996-11-05 2000-09-27 Smithkline Beecham Corp Wachstumsfaktor-antagonisten von hepatozyten
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
DK0950416T3 (da) * 1997-03-14 2007-02-26 Daiichi Seiyaku Co Anvendelse af TCF-II til behandling af cancerrelateret tab af kropsvægt, anæmi og TNF-forhöjelse
GB9709453D0 (en) * 1997-05-10 1997-07-02 Imp Cancer Res Tech Polypedtides and their use in therapy
ITMI980179A1 (it) * 1998-01-30 1999-07-30 Dompe Spa Proteine ricombinanti derivate da hgf e msp
ITMI980180A1 (it) * 1998-01-30 1999-07-30 Dompe Spa Proteine ricombinanti derivate da hgf e msp
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
EP1220942A1 (de) * 1999-09-27 2002-07-10 Human Genome Sciences, Inc. 41 humane sekretierte proteine
US20080241835A1 (en) * 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
CA2392366A1 (en) * 1999-11-24 2001-05-31 Human Genome Sciences, Inc. Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies
WO2001098347A1 (en) * 2000-06-22 2001-12-27 Nippon Zenyaku Kogyo Ltd. Canine liver cell growth factor
EP1234583A1 (de) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US20070073047A1 (en) * 2002-06-10 2007-03-29 Biogen Idec Ma Inc. Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
AU2003277283A1 (en) * 2002-10-07 2004-05-04 Genentech, Inc. Hepatocyte growth factor variants
US20050214859A1 (en) * 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
WO2004093892A2 (en) * 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
EP1695982B1 (de) 2003-12-16 2013-01-23 Toshikazu Nakamura Glycosylierungsdefizienter hepatocytenwachstumsfaktor
KR100956913B1 (ko) * 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
US7807177B2 (en) * 2004-01-27 2010-10-05 Toshikazu Nakamura Segment of glycosylation-deficient HGFalpha-chain
US7754448B2 (en) 2004-03-03 2010-07-13 Hoffman-La Roche Inc. Method for the recombinant expression of an N-terminal fragment of hepatocyte growth factor
JP4511589B2 (ja) 2004-03-03 2010-07-28 エフ．ホフマン−ラ ロシュ アーゲー 肝細胞成長因子のｎ末端フラグメントを精製するための方法
AU2005267720B2 (en) 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
CA2605037C (en) 2005-04-15 2015-02-24 Genentech, Inc. Hgf beta chain variants
WO2009111707A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
BR112013030472A2 (pt) 2011-06-30 2019-09-24 Genentech Inc formulação farmacêutica, artigo de fabricação e método
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
KR102793810B1 (ko) * 2017-08-04 2025-04-11 가톨릭대학교 산학협력단 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학적 조성물
CN109535243B (zh) 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814981C3 (de) * 1978-04-07 1981-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Faktor zur Stimulation der Proliferationsrate von Leberzellen
DE2914903C2 (de) * 1979-04-12 1981-08-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Leberzellwachstumfaktor
JPS5862116A (ja) * 1981-10-09 1983-04-13 Mitsubishi Chem Ind Ltd 肝細胞の増殖促進物質
JPS6045534A (ja) * 1983-08-22 1985-03-12 Otsuka Pharmaceut Co Ltd 肝実質細胞増殖因子
JPS60243019A (ja) * 1984-05-17 1985-12-03 Mitsubishi Chem Ind Ltd 肝細胞増殖因子
JPH0635480B2 (ja) * 1985-08-23 1994-05-11 大塚製薬株式会社 肝実質細胞増殖因子
JPS62161730A (ja) * 1986-01-10 1987-07-17 Mitsubishi Chem Ind Ltd 細胞増殖因子の産生誘発剤
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
ES2005159A6 (es) * 1987-04-14 1989-03-01 Inst Llorente S A Procedimiento para diagnostico y seguimiento de hepatopatias mediante determinacion de factor de crecimiento hepatico en plasma yno suero sanguineo.
JPS643199A (en) * 1987-06-25 1989-01-06 Yasushi Daikuhara Monoclonal antibody
JPS6427491A (en) * 1987-07-14 1989-01-30 Yasushi Daikuhara Monoclonal antibody
JPH02213A (ja) * 1987-10-19 1990-01-05 Taiho Yakuhin Kogyo Kk 生理活性ペプチド持続製剤
JP3030312B2 (ja) * 1988-12-12 2000-04-10 敏一 中村 成熟肝実質細胞増殖因子（ｉ）
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
JPH03130091A (ja) * 1989-06-05 1991-06-03 Toyobo Co Ltd 組換ヒト肝実質細胞増殖因子
JP2706704B2 (ja) * 1989-06-05 1998-01-28 敏一 中村 組換ヒト肝実質細胞増殖因子
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
JPH03204899A (ja) * 1989-09-21 1991-09-06 Otsuka Pharmaceut Co Ltd ヒト肝再生因子、そのｄｎａ塩基配列、該配列を含むプラスミド及び形質転換体並びにリコンビナント肝再生因子
JPH03255096A (ja) * 1990-03-01 1991-11-13 Toyobo Co Ltd 組換ラット肝実質細胞増殖因子
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
JPH0413696A (ja) * 1990-05-08 1992-01-17 Mochida Pharmaceut Co Ltd 新規生理活性物質
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JPH0436189A (ja) * 1990-05-30 1992-02-06 Otsuka Pharmaceut Co Ltd 肝細胞増殖因子の製造方法
EP0461560B1 (de) * 1990-06-11 1998-11-18 Toshikazu Nakamura Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
DE69131069T2 (de) * 1990-07-13 1999-07-15 Snow Brand Milk Products Co., Ltd., Sapporo, Hokkaido Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
JPH04120097A (ja) * 1990-09-07 1992-04-21 Agency Of Ind Science & Technol 肝細胞増殖因子
ATE256736T1 (de) * 1990-09-14 2004-01-15 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
JP3072628B2 (ja) * 1990-11-19 2000-07-31 敏一 中村 ヒト肝実質細胞増殖因子をコードする染色体ｄｎａ
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants

Also Published As

Publication number Publication date
ES2181689T3 (es) 2003-03-01
EP0642580B1 (de) 2002-08-21
DE69332221D1 (de) 2002-09-26
EP0642580A1 (de) 1995-03-15
WO1993023541A1 (en) 1993-11-25
JPH07508420A (ja) 1995-09-21
US5547856A (en) 1996-08-20
PT642580E (pt) 2003-01-31
DE69332221T2 (de) 2003-04-17
CA2118012A1 (en) 1993-11-25
DK0642580T3 (da) 2002-12-23
JP2004000236A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
ATE222603T1 (de) Hepatozytwachstumfaktor variante
DE69825904D1 (de) Mutante alpha-amylase mit zusätzlicher disulfidverbindung
ATE77650T1 (de) Enzymatische waschmittelzusammensetzung.
MX9804262A (es) Inhibidores derivados de d-aminoacidos de proteasas de cisteina y serina.
ATE184289T1 (de) Ribosomen-inaktivierende proteine, inaktive vorläuferformen derselben, verfahren zur herstellung und eine methode zur nutzung
DE3785036D1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
ATE103632T1 (de) Enzymatische waschmittelzusammensetzung und verfahren zum stabilisieren der enzyme.
FI862756A0 (fi) Fibroektiner.
GR3031646T3 (en) Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors.
EP0975353A4 (de) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
DE69333639D1 (en) Trypsininhibitoren
DK0907724T3 (da) Von Willebrand-faktor-multimerase
ATE131066T1 (de) Mittel zur hemmung von hiv-proteasen.
DE3684403D1 (de) Verfahren zur erhoehung der produktion des gewebeplasminogenaktivators und des einzelkettenurokinase-plasminogenaktivators.
DE69331371D1 (de) Dipeptidylaminopeptidase von Dictyostelium
FI956178L (fi) Varsibromelaiiniproteaasin lääkekäyttö
DE60029624D1 (de) Homologe enzyme der humanen heparanase sowie alternative spleissformen davon
AU2163588A (en) Stabilization of enzymes by inhibiting proteolytic enzyme contaminants
NZ209250A (en) Alpha-allenic-alpha-amino acids and pharmaceutical compositions
AU96847S (en) Sofa-bed
AU133847S (en) Jumper valve
AU124219S (en) Edging
AU127561S (en) Edging

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification